Spectral MD Awarded an Additional $8.2M of Funding From BARDA
DALLAS - August 30, 2022 - (Newswire.com)
Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company with proprietary AI and optical technology for faster and more accurate treatment decisions in wound care, announces it has been awarded $8.2 million in additional funding by the US Biomedical Advanced Research and Development Authority (BARDA). This funding supplements the original award announced on September 6, 2021, and brings the total funding commitment received by Spectral MD to over $100 million since 2013. The additional funding will further accelerate the commercialization of the Company's DeepView® Wound Imaging System ("DeepView®") by expanding the number of sites for the clinical training study for burn wounds, increasing DeepView®'s interoperability with health systems' electronic health records ("EHR"), and accelerating the Company's manufacturing readiness.
"We are honored to receive this funding to deliver technology assisting with BARDA's preparedness goal to rapidly develop safe, effective medical countermeasures accessible to all Americans," says Wensheng Fan, Chief Executive Officer of Spectral MD. "Importantly, this award expedites bringing this transformative technology to market and will ultimately change the standard of care for burn diagnosis and treatment in the U.S."
Spectral MD will expand DeepView®'s burn training study to include additional pediatric sites and US Emergency Departments ("EDs"). The Company anticipates the additional pediatric clinical data will increase the robustness and accuracy of DeepView®'s wound healing prediction in pediatric patients from the current level of 88%. The addition of EDs will facilitate establishing a clinical benchmark for DeepView®'s ED burn healing assessment, which we anticipate will have a major impact in the delivery of care for burns which is currently a challenge for the diagnosis of burn wounds.
With this award, additional interoperability features will be added to DeepView® that allow for integration with major US EHR systems, such as EPIC, Cerner, and others. This is an important feature, as US federal and state governments are heavily promoting the adoption of EHRs to improve care quality, safety, efficiency, cost-savings and to reduce health disparities.
The award will also significantly increase the Company's DeepView® system production readiness in collaboration with its manufacturing partner utilizing validated current Good Manufacturing Practice ("cGMP") for scaled production.
This project has been supported in whole or in part with federal funds from the Department of Health and Human Services; the Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under Contract number 75A50119C00033. Learn more about BARDA: https://www.medicalcountermeasures.gov. Funding support for DeepView's use in burn triage and treatment decisions has also been provided by US National Science Foundation (NSF), US National Institutes of Health (NIH) and US Defense Health Agency (DHA).
About Spectral MD:
We are a dedicated team of forward-thinkers striving to revolutionize the management of wound care by "Seeing the Unknown" ® with our DeepView®Wound Imaging System.
Press Release Service by Newswire.com
Original Source: Spectral MD Awarded an Additional $8.2M of Funding From BARDA
WELLCORNER, LLC LAUNCHES NEW HEALTH & WELLNESS PRODUCT LINES FOR CANCER PATIENTS AT ITS...
Bitcasino to Use Estonian ESTCube-2 Satellite to Send Bitcoin Into Space
Addison Group Earns Top Spot on 6 U.S. & Global SIA Largest Staffing Firms...
Cortechs.ai Awarded Million Dollar NIH Grant for Early Diagnosis of Alzheimer’s Disease Using Advanced...
SAN DIEGO - August 29, 2022 - (Newswire.com)
Cortechs.ai has received a $1.35 million, 2.5-year grant from the National Institutes of Health (NIH), National Institute on Aging to advance Alzheimer's Disease (AD) diagnosis. The grant will allow Cortechs.ai to deliver an automated AI solution in a clinical setting to enable physicians to quickly determine a patient's risk of developing AD and monitor disease progression and response to treatment.
"We are thrilled to receive support from the NIA to further advance this promising technology in the area of Alzheimer's Disease diagnosis," said Nathan White, CTO of Cortechs.ai and co-inventor of Restriction Spectrum Imaging. "The development of new therapeutics for prevention and treatment of the disease would greatly benefit from robust, objective quantitative imaging biomarkers that reflect subtle underlying pathological brain changes that occur early in the disease process."
Alzheimer's Disease, a progressive neurodegenerative disorder, is characterized by β-amyloid deposits and neurofibrillary tangles preceding neuronal loss and cognitive decline. While diffusion imaging has been used effectively in diseases involving specific white matter pathways, the recent advances in diffusion imaging techniques - particularly multi-compartmental models for successfully quantifying microstructural changes - now enable the effective use of diffusion imaging in Alzheimer's Disease. The project aims to use an advanced diffusion MRI technique called Restriction Spectrum Imaging to quantify the subtle microstructural changes in Alzheimer's patients' brains, making it possible to detect pathological changes in the brain without an autopsy.
Cortechs Labs holds the patent on "Restriction Spectrum Imaging." The project titled "Quantifying microstructural changes in Alzheimer's Disease using Restriction Spectrum Imaging" is one of many projects for which Cortechs.ai received research grants.
---
About Cortechs.ai
Cortechs.ai develops and markets breakthrough medical device software solutions capable of automatically segmenting and quantifying brain structures, making quantitative analysis of the human brain a routine part of clinical practice. Cortechs.ai's cutting-edge brain imaging analysis provides neurologists, radiologists, and clinical researchers worldwide with a convenient and cost-effective means to quantify subcortical structures to help assess a variety of neurological conditions, such as Alzheimer's disease, epilepsy, multiple sclerosis, brain trauma, and brain development abnormalities. Please visit cortechs.ai for further information.
About NIA, National Institute on Aging (Institute of NIH)
NIA, one of the 27 Institutes and Centers of NIH, leads the federal government in conducting and supporting research on aging and the health and well-being of older people. The Institute seeks to understand the nature of aging, the aging process, and diseases and conditions associated with growing older to extend the healthy, active years of life. Please visit nia.nih.gov for further information.
---
Media Contact:
Cortechs.ai
Dani Kuta
Marketing Manager
+1 858 459-9700
Media Contact:
NIH, National Institute on Aging
+1 301 496-1752
Press Release Service by Newswire.com
Original Source: Cortechs.ai Awarded Million Dollar NIH Grant for Early Diagnosis of Alzheimer's Disease Using Advanced Diffusion MRI Technique
The California Food is Medicine Coalition Announces New Director to Advance Medically Tailored Nutrition...
Zeto and Next Gen Neuro Partner for Remote EEG Monitoring
With Expanded Outdoor Features, Lifestyle Healing Institute Integrates Traditional and Holistic Medicine
Leading Medical Device and Hospital Bed Rental Partner US Med-Equip Makes Inc. 5000 Fastest-Growing...
HOUSTON - August 26, 2022 - (Newswire.com)
US Med-Equip, which partners with top hospitals across the nation to provide rented medical equipment and beds for patients in their care, is again named as one of the nation's fastest-growing private companies in Inc. magazine's annual Inc. 5000 list.
Houston-based US Med-Equip is a healthcare company specializing in the rental, sales, service and asset management of movable medical equipment—diagnostic and clinical devices ranging from infusion pumps to ventilators, baby incubators and more. US Med-Equip has more than 135,000 movable medical devices, beds, and therapeutic support services available for rent at a moment's notice from nearly 100 locations across the country, with more on the way.
Hospitals are streamlining processes and turning to smarter options from trusted partners like US Med-Equip to ensure they provide patients the best care possible. Hospitals count on US Med-Equip's growing team of 700 employees for top medical equipment and the critical technology and services to maintain it. The company is expanding rapidly to meet growing demand nationwide and recently acquired Freedom Medical.
From ventilators to bariatric beds, hospitals place equipment orders from US Med-Equip 24 hours a day, 7 days a week, based on current or anticipated need. The US Med-Equip team works with urgency to deliver the life-saving equipment within a two-hour window plus drive time.
With three-year growth of 250%, USME is appearing on the Inc. 5000 list for the 10th time—an achievement attained by only a small fraction of listed companies.
"Our growing team's commitment to our shared purpose—to support the important work healthcare providers do to help patients heal—is what continues to drive our growth," US Med-Equip CEO Greg Salario said.
More about the Inc. 5000
The Inc. 5000 is a list of the fastest-growing private companies in the nation. This prestigious list has become the hallmark of entrepreneurial success. The 2022 Inc. 5000 is ranked according to percentage revenue growth when comparing 2018 and 2021.
MEDIA CONTACT: US Med-Equip, news[at]usmedequip[dot]com, 713.983.8860
Press Release Service by Newswire.com
Original Source: Leading Medical Device and Hospital Bed Rental Partner US Med-Equip Makes Inc. 5000 Fastest-Growing Private Company List for 10th Time
